Medizen Humancare메디젠휴먼케어

Medizen Humancare's shares have fallen sharply over the past year, and the data shows no current financial statements or valuation metrics to explain the move.

Medizen Humancare is a KONEX-listed digital healthcare company focused on genomic analysis, including hereditary cancer and prenatal genetic testing, according to its profile. The share price closed at ₩1,350 on 2026-10-28, with a market value of about ₩4.1B, down 25% over one year and 45% over three months. The data contains no trailing financials, annual figures, or valuation ratios, so the current business scale cannot be assessed from it.

What stands out

• The share price is ₩1,350, well below its 52-week high of ₩4,015 and above its 52-week low of ₩1,233.
• Returns were -32.5% over one month, -45.2% over three months and -25% over one year.
• No annual or trailing financial statements are included, so revenue, profit and cash position are not available in this data.
• Valuation ratios (P/E, P/B, P/S, EV/EBITDA) are not available, and dividend yield is 0%.
• Recent filings are mostly investor relations events, an AGM in March 2026, and a September 2026 exercise of convertible share conversion rights; no news headlines were provided.
• Foreign ownership is 0%, and 20-day net flows show retail buying of about ₩3.4M with no foreign or institutional flows.

What to watch

• Upcoming filed financial statements, since the data does not show any recent revenue or profit figures.
• Further convertible share conversions noted in the September 2026 filing, which can add shares outstanding.
• The lawsuit filed or ruled on in February 2026, whose details are not described in the data.